A case report of the long treatment experience of a Sézary syndrome responder patient: 16 years through all the systemic and innovative therapies
- 13 January 2019
- journal article
- case report
- Published by Wiley in Hematological Oncology
- Vol. 37 (2) , 202-204
Abstract
Existing therapies for Sézary syndrome (SS) are limited in efficacy and in disease control, and patients have very poor prognosis. Here, we report a case report of a patient who has a 16‐year history of SS and related treatments (both standard and experimental). In particular, two drugs, one conventional (gemcitabine) and one experimental (mogamulizumab), were able to induce long lasting response. Patient refused to undergo allogeneic stem cell transplantation. After eleven lines of therapeutic approaches, the patient is in very good partial response and free of therapy at the latest available follow‐up.Keywords
This publication has 9 references indexed in Scilit:
- Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trialThe Lancet Oncology, 2018
- Cutaneous T-cell lymphomas: Focusing on novel agents in relapsed and refractory diseaseCancer Treatment Reviews, 2017
- Cutaneous T‐cell lymphoma: 2017 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2017
- Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell LymphomaClinical Cancer Research, 2017
- European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017European Journal of Cancer, 2017
- Sézary syndrome without erythroderma: A review of 16 cases at Mayo ClinicJournal of the American Academy of Dermatology, 2017
- Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndromeHematology-American Society Hematology Education Program, 2015
- Mycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markersAustralasian Journal of Dermatology, 2015
- Sézary syndrome: A study of 176 patients at Mayo ClinicJournal of the American Academy of Dermatology, 2012